LEAP Trio

  • Research type

    Research Study

  • Full title

    Follow-up of LEAP Participants and Their Families: LEAP Trio

  • IRAS ID

    195451

  • Contact name

    Gideon Lack

  • Contact email

    gideon.lack@kcl.ac.uk

  • Sponsor organisation

    National Institute of Allergy and Infectious Diseases (NIAID)

  • Clinicaltrials.gov Identifier

    195451, IRAS Project ID

  • Duration of Study in the UK

    1 years, 7 months, 30 days

  • Research summary

    Research Summary

    Peanut Allergy (PA) is a recognised public health concern. The early introduction of specific food allergen(s) to infant diets has proven to be a successful strategy for the prevention of food allergy. The Learning Early about Peanut Allergy (LEAP) Study demonstrated that the introduction of peanut to the infant diet before 11 months of age protected against the development of PA in a high-risk, atopic population. The LEAP-On Study demonstrated that subsequent avoidance of peanut for a year did not influence the protective effect of the intervention. All LEAP participants will now be offered enrolment in a follow-on study (LEAP Ad-Lib), a second study will assess siblings (LEAP Siblings) and a final study will assess parents (LEAP Parents). Together these three studies are known as LEAP Trio.
    The primary objective of LEAP Trio is to assess whether early consumption of peanuts by high-risk infants results in a decreased risk of peanut allergy in children approximately 10 years of age, i.e. are they tolerant regardless of consumption or avoidance of peanut. The secondary objective is to determine the prevalence of sensitisation in younger siblings of LEAP participants who consumed peanut compared to younger siblings of LEAP participants who avoided peanut, i.e. does the level of peanut in the home environment influence the rates of sensitisation in younger siblings. Genetic samples from parents will be taken and stored for use in a genetic analysis comparing LEAP participants, their siblings and parents.
    LEAP Trio participants will undergo allergy assessments including questionnaires, skin and blood testing and a supervised peanut oral food challenge (no OFC in parents). It will be a single site study based at the Evelina London, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID).

    Summary of Results

    The summary of study results for Protocol ITN070AD (LEAP Trio) are posted on ClinicalTrials.gov (https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT03546413%3Fterm%3DLEAP%2520TRio%26rank%3D1%26tab%3Dresults&data=05%7C02%7Cfulham.rec%40hra.nhs.uk%7C1d552585d8c04944f6a908dd02fe9463%7C8e1f0acad87d4f20939e36243d574267%7C0%7C0%7C638670014617965652%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=9QrV1oQGxXzk2atRsCI9gR0zKDJqFLqFJNYoecY07eI%3D&reserved=0)

    The complete protocol is publically available on ClinicalTrials.gov (https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fcdn.clinicaltrials.gov%2Flarge-docs%2F13%2FNCT03546413%2FProt_000.pdf&data=05%7C02%7Cfulham.rec%40hra.nhs.uk%7C1d552585d8c04944f6a908dd02fe9463%7C8e1f0acad87d4f20939e36243d574267%7C0%7C0%7C638670014617987613%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=GRWoQpValpub0%2FjFqi4%2Fyo%2BN8vpUlXzamBlFnz2JsOM%3D&reserved=0) and included in the publication:
    Protocol for: George Du Toit, Michelle F. Huffaker, Suzana Radulovic, et al. Follow-up to Adolescence after Early Peanut Introduction for Allergy Prevention. NEJM Evid. DOI: 10.1056/EVIDoa2300311 (https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fevidence.nejm.org%2Fdoi%2Ffull%2F10.1056%2FEVIDoa2300311%23ap1&data=05%7C02%7Cfulham.rec%40hra.nhs.uk%7C1d552585d8c04944f6a908dd02fe9463%7C8e1f0acad87d4f20939e36243d574267%7C0%7C0%7C638670014618010594%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=KnggR5aNVF7D0BT0x7spJe126J5cSbtukcVzG7JvNao%3D&reserved=0).

    The summary of study results for Protocol ITN070AD (LEAP Trio) are posted on ClinicalTrials.gov (https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT03546413%3Fterm%3DLEAP%2520TRio%26rank%3D1%26tab%3Dresults&data=05%7C02%7Cfulham.rec%40hra.nhs.uk%7C58c2a6a00a5242d937ae08de16266a47%7C8e1f0acad87d4f20939e36243d574267%7C0%7C0%7C638972551410526293%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=M3uvctqg%2F%2BaWJMR%2Fs1%2BDcJ%2BB23PRFG0ArQfToIg839k%3D&reserved=0)

  • REC name

    London - Fulham Research Ethics Committee

  • REC reference

    17/LO/1609

  • Date of REC Opinion

    28 Nov 2017

  • REC opinion

    Further Information Favourable Opinion